Kymera Therapeutics

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

Stein,,Switzerland,-,February,18,,2020:,Novartis,Is,The,Second

Analyst Color

Biotech

Equities

Large Cap

News

Health Care

Analyst Ratings

Trading Ideas

General

ABBV

AMGN

BIIB

CATX

INCY

KYMR

REGN

YMAB

Novartis aims to enhance Pluvicto&#39;s market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights

Analysts

Upgrades

Pre-Market Outlook

OLLI

This BJ&#39;s Wholesale Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday

QuantumScape QS Stock

Mid Cap

Movers

APGE

CRNX

JOBY

LNTH

PLUG

SMMT

XPEV

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit Therapeutics, Plug Power and XPeng Inc.

XPeng &amp; QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

Kymera Therapeutics Inc

Earnings

Press Releases

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Kymera Therapeutics to Participate in Upcoming February Investor Conferences

Management

NAYA Biosciences Announces Nomination of New Board Members

Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

BDTX

NAYA

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Apogee Therapeutics

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

Beam Therapeutics

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Denali Therapeutics

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Galapagos NV - American Depositary Shares

Galapagos

ImmunityBio

Disc Medicine

Janux Therapeutics

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Soleno Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Veracyte

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Citigroup

HC Wainwright & Co.

Stephens & Co.

Leerink Partners

BTIG

Comments

Kymera Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga